Murray Barclay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8591234/publications.pdf

Version: 2024-02-01

187 papers	16,651 citations	30070 54 h-index	16183 124 g-index
191 all docs	191 docs citations	191 times ranked	22037 citing authors

#	Article	IF	Citations
1	Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children. Journal of Crohn's and Colitis, 2022, 16, 1835-1844.	1.3	6
2	A nationwide survey on therapeutic drug monitoring of antiâ€tumour necrosis factor agents for inflammatory bowel disease. Internal Medicine Journal, 2021, 51, 341-347.	0.8	6
3	Comparison of Risk Scoring Systems in Hospitalised Patients who Develop Upper Gastrointestinal Bleeding. GastroHep, 2021, 3, 5-11.	0.6	6
4	Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Alimentary Pharmacology and Therapeutics, 2021, 53, 810-820.	3.7	22
5	A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2020, 26, 1098-1109.	1.9	31
6	Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urateâ€Lowering Responseâ€”In Search of a Minimum Effective Oxypurinol Concentration. Clinical and Translational Science, 2020, 13, 110-115.	3.1	6
7	Clinical decision support in a hospital electronic prescribing system informed by local data: experience at a tertiary New Zealand centre. Internal Medicine Journal, 2020, 50, 1225-1231.	0.8	3
8	Tu1496 THE ABC SCORE ACCURATELY PREDICTS MORTALITY IN HOSPITALIZED PATIENTS THAT DEVELOP UPPER GASTROINTESTINAL BLEEDING. Gastrointestinal Endoscopy, 2020, 91, AB590-AB591.	1.0	0
9	Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Pharmacology, 2020, 55, 41-46.	3.5	17
10	Systematic review with metaâ€analysis: SARSâ€CoVâ€2 stool testing and the potential for faecalâ€oral transmission. Alimentary Pharmacology and Therapeutics, 2020, 52, 1276-1288.	3.7	113
11	A 1 g dose of intravenous iron is sufficient to treat iron deficiency anaemia. Internal Medicine Journal, 2020, 50, 1563-1566.	0.8	1
12	Infliximab and adalimumab concentrations and antiâ€drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal, 2019, 49, 513-518.	0.8	8
13	Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports, 2019, 9, 10351.	3.3	75
14	Mo1290 â€“ Comparison of Risk Scoring Systems in Hospitalized Patients that Develop Upper Gastrointestinal Bleeding. Gastroenterology, 2019, 156, S-749.	1.3	0
15	P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDocÂ® in the care of inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2019, 13, S432-S433.	1.3	1
16	A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate. Journal of Clinical Rheumatology, 2019, 25, 284-287.	0.9	4
17	P523 Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S374-S374.	1.3	0
18	Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. Gastroenterology, 2019, 156, 11-14.	1.3	27

#	Article	IF	Citations
19	New Zealand Society of Gastroenterology Guidelines on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. New Zealand Medical Journal, 2019, 132, 46-62.	0.5	0
20	Combination Immunosuppression in IBD. Inflammatory Bowel Diseases, 2018, 24, 539-545.	1.9	45
21	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (<scp>AAA</scp> Study). Alimentary Pharmacology and Therapeutics, 2018, 47, 1092-1102.	3.7	38
22	Editorial: vedolizumab as a treatment and cause of extraâ€intestinal manifestations of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 535-536.	3.7	0
23	The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 2018, 84, 937-943.	2.4	11
24	How to prevent allopurinol hypersensitivity reactions?. Rheumatology, 2018, 57, i35-i41.	1.9	43
25	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis, 2018, 12, 610-620.	1.3	67
26	â€˜It feels like being trapped in an abusive relationshipâ€™: bullying prevalence and consequences in the New Zealand senior medical workforce: a cross-sectional study. BMJ Open, 2018, 8, e020158.	1.9	21
27	Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine. Inflammatory Bowel Diseases, 2018, 24, 892-896.	1.9	13
28	How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research and Therapy, 2018, 20, 255.	3.5	9
29	Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2606-2612.	1.9	4
30	Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 2018, 57, 2183-2189.	1.9	6
31	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nature Communications, 2018, 9, 2427.	12.8	159
32	Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 2017, 83, 2015-2026.	2.4	17
33	Deterministic identifiability of population pharmacokinetic and pharmacokineticâ€“pharmacodynamic models. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 415-423.	1.8	9
34	A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 2017, 76, 1522-1528.	0.9	107
35	Comment on: â€œEffect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Studyâ€• Clinical Pharmacokinetics, 2017, 56, 207-208.	3.5	3
36	Review article: consensus statements on therapeutic drug monitoring of antiâ€tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 46, 1037-1053.	3.7	225

#	Article	IF	Citations
37	Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Annals of the Rheumatic Diseases, 2017, 76, 2065-2070.	0.9	53
38	A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 2017, 73, 71-78.	1.9	14
39	The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. Arthritis Research and Therapy, 2017, 19, 283.	3.5	24
40	AB1031â€...Anti-drug antibodies: assay performance in patients treated with ANTI-TNF biodrugs. , 2017, , .		0
41	Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab. Therapeutic Drug Monitoring, 2016, 38, 32-41.	2.0	24
42	Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 2016, 81, 277-289.	2.4	46
43	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	6.2	21
44	Burnout prevalence in New Zealand's public hospital senior medical workforce: a cross-sectional mixed methods study. BMJ Open, 2016, 6, e013947.	1.9	48
45	The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees-a randomised comparative trial. New Zealand Medical Journal, 2016, 129, 53-63.	0.5	3
46	Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers. Pharmacogenomics Journal, 2015, 15, 414-421.	2.0	5
47	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nature Genetics, 2015, 47, 172-179.	21.4	280
48	Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics, 2015, 16, 891-903.	1.3	43
49	Sa1269 Adjunctive Allopurinol in Azathioprine/6-Mercaptopurine Non-Responders Optimises 6-Thioguanine Nucleotide Production and Improves Clinical Outcomes in Inflammatory Bowel Disease: The Prospective, Multicentre, Double Blind, Dose-Ranging AAA Study. Gastroenterology, 2015, 148, S-277.	1.3	0
50	Smoking behaviour modifies IL23râ€associated disease risk in patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 299-307.	2.8	18
51	Assessment of the Relationship Between Methotrexate Polyglutamates in Red Blood Cells and Clinical Response in Patients Commencing Methotrexate for Rheumatoid Arthritis. Clinical Pharmacokinetics, 2014, 53, 1161-1170.	3.5	16
52	Thirteen Years' Experience of Pharmacokinetic Monitoring and Dosing of Busulfan. Therapeutic Drug Monitoring, 2014, 36, 86-92.	2.0	24
53	Impaired response or insufficient dosage?â€"Examining the potential causes of â€œinadequate responseâ€•to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism, 2014, 44, 170-174.	3.4	43
54	Therapeutic drug monitoring in rheumatic diseases: utile or futile?. Rheumatology, 2014, 53, 988-997.	1.9	20

#	Article	IF	Citations
55	PACSIN2 Does Not Influence Thiopurine-Related Toxicity In Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2014, 109, 925-927.	0.4	7
56	Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C. Drugs in R and D, 2014, 14, 113-123.	2.2	38
57	Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. British Journal of Clinical Pharmacology, 2014, 77, 493-497.	2.4	13
58	Coagulation assays and plasma fibrinogen concentrations in realâ€world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 2014, 78, 630-638.	2.4	16
59	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 2013, 69, 1411-1421.	1.9	26
60	An Envirogenomic Signature Is Associated with Risk of IBD-Related Surgery in a Population-Based Crohnâ€™s Disease Cohort. Journal of Gastrointestinal Surgery, 2013, 17, 1643-1650.	1.7	6
61	A Population Pharmacokinetic Model for Low-Dose Methotrexate and its Polyglutamated Metabolites in Red Blood Cells. Clinical Pharmacokinetics, 2013, 52, 475-485.	3.5	22
62	Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring. British Journal of Clinical Pharmacology, 2013, 75, 569-570.	2.4	5
63	Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Internal Medicine Journal, 2013, 43, 778-783.	0.8	11
64	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. PLoS Genetics, 2013, 9, e1003723.	3.5	185
65	Biological variation of thiopurine methyltransferase enzyme activity: when has a significant change taken place?. Annals of Clinical Biochemistry, 2013, 50, 473-478.	1.6	5
66	Preanalytical stringency: what factors may confound interpretation of thiopurine S-methyl transferase enzyme activity?. Annals of Clinical Biochemistry, 2013, 50, 479-484.	1.6	6
67	A Simple High-Performance Liquid Chromatography Method for Simultaneous Determination of Three Triazole Antifungals in Human Plasma. Antimicrobial Agents and Chemotherapy, 2013, 57, 484-489.	3.2	32
68	Perianal Disease Combined With NOD2 Genotype Predicts Need for IBD-related Surgery in Crohnâ€™s Disease Patients From a Population-based Cohort. Journal of Clinical Gastroenterology, 2013, 47, 242-245.	2.2	13
69	Use and Predictors of Oral Complementary and Alternative Medicine by Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 767-778.	1.9	60
70	Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World Journal of Gastroenterology, 2013, 19, 6656.	3.3	17
71	Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. Rheumatology, 2012, 51, 1670-1676.	1.9	38
72	The Spectrum of Perianal Crohnâ€™s Disease in a Population-Based Cohort. Diseases of the Colon and Rectum, 2012, 55, 773-777.	1.3	182

#	Article	IF	Citations
73	Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1546-1554.	2.8	28
74	Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?. British Journal of Clinical Pharmacology, 2012, 74, 734-740.	2.4	15
75	Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 404, 2091-2096.	3.7	9
76	Hostâ€“microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	27.8	4,038
77	Clinical and Genetic Risk Factors for Perianal Crohn's Disease in a Population-Based Cohort. American Journal of Gastroenterology, 2012, 107, 589-596.	0.4	57
78	High <scp>TPMT</scp> enzyme activity does not explain drug resistance due to preferential 6â€methylmercaptopurine production in patients on thiopurine treatment. Alimentary Pharmacology and Therapeutics, 2012, 35, 1181-1189.	3.7	49
79	Letter: <scp>TPMT</scp> â€“ not all that glitters is gold; authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 209-210.	3.7	0
80	Independent Replication of an Association of CNVR7113.6 with CrohnÊ¼s Disease in Caucasians. Inflammatory Bowel Diseases, 2012, 18, 305-311.	1.9	1
81	Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Human Immunology, 2011, 72, 1117-1127.	2.4	18
82	Allopurinol might improve response to azathioprine and 6â€mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 49-54.	2.8	37
83	Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males. Alimentary Pharmacology and Therapeutics, 2011, 33, 855-856.	3.7	20
84	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	21.4	1,201
85	Relationship Between Serum Urate and Plasma Oxypurinol in the Management of Gout: Determination of Minimum Plasma Oxypurinol Concentration to Achieve a Target Serum Urate Level. Clinical Pharmacology and Therapeutics, 2011, 90, 392-398.	4.7	48
86	Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, E19-E21.	1.9	0
87	Differential association of two PTPN22 coding variants with CrohnÊ¼s disease and ulcerative colitis. Inflammatory Bowel Diseases, 2011, 17, 2287-2294.	1.9	73
88	Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis and Rheumatism, 2011, 63, 412-421.	6.7	199
89	Effects of Changing from Oral to Subcutaneous Methotrexate on Red Blood Cell Methotrexate Polyglutamate Concentrations and Disease Activity in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2540-2547.	2.0	54
90	Clozapine-Induced Gastrointestinal Hypomotility. Australasian Psychiatry, 2011, 19, 450-451.	0.7	4

#	Article	IF	Citations
91	NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World Journal of Gastroenterology, 2011, 17, 2829-37.	3.3	18
92	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics and Genomics, 2010, 20, 367-376.	1.5	57
93	Dietary factors in chronic inflammation: Food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 690, 123-138.	1.0	78
94	Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populationsâ€. Inflammatory Bowel Diseases, 2010, 16, 2080-2089.	1.9	15
95	Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving longâ€term methotrexate therapy. Arthritis and Rheumatism, 2010, 62, 359-368.	6.7	77
96	Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. British Journal of Surgery, 2010, 97, 1103-1109.	0.3	14
97	Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes and Immunity, 2010, 11, 351-356.	4.1	92
98	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	21.4	2,284
99	Populationâ€based cases control study of inflammatory bowel disease risk factors. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 325-333.	2.8	192
100	Azathioprine and allopurinol: A twoâ€edged interaction. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 653-655.	2.8	41
101	Populationâ€based epidemiology study of autoimmune hepatitis: A disease of older women?. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1681-1686.	2.8	157
102	KCNN4 Gene Variant Is Associated With Ileal Crohn's Disease in the Australian and New Zealand Population. American Journal of Gastroenterology, 2010, 105, 2209-2217.	0.4	59
103	Consolidation of Evidence for Association of the KIAA1109-TENR-IL2-IL21 rs6822844 Variant With Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 1204-1205.	0.4	12
104	Association of Higher DEFB4 Genomic Copy Number With Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 354-359.	0.4	83
105	Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. Genes and Immunity, 2010, 11, 509-514.	4.1	3
106	Allopurinolâ€“thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?. Pharmacogenomics, 2010, 11, 1505-1508.	1.3	9
107	SLC11A1polymorphisms in inflammatory bowel disease andMycobacterium aviumsubspeciesparatuberculosisstatus. World Journal of Gastroenterology, 2010, 16, 5727.	3.3	14
108	Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population. Gastroenterology Research and Practice, 2009, 2009, 1-9.	1.5	19

#	Article	IF	Citations
109	Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: a case-control study. BMC Research Notes, 2009, 2, 52.	1.4	22
110	Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 1784-1793.	1.9	36
111	Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving longâ€term methotrexate treatment. Arthritis and Rheumatism, 2009, 60, 2248-2256.	6.7	94
112	Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3025-3030.	2.3	5
113	Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis: Table 1. Annals of the Rheumatic Diseases, 2009, 68, 154-155.	0.9	25
114	Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Human Immunology, 2009, 70, 440-446.	2.4	25
115	Mushroom intolerance: a novel dietâ€“gene interaction in Crohn's disease. British Journal of Nutrition, 2009, 102, 506.	2.3	31
116	Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 3299-3308.	6.7	161
117	Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Digestive and Liver Disease, 2008, 40, 723-730.	0.9	22
118	Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes and Immunity, 2008, 9, 561-565.	4.1	142
119	Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-Fold. Clinical Gastroenterology and Hepatology, 2008, 6, 654-660.	4.4	77
120	Incidence of Mycobacterium avium Subspecies paratuberculosis in a Population-Based Cohort of Patients With Crohn's Disease and Control Subjects. American Journal of Gastroenterology, 2008, 103, 1168-1172.	0.4	54
121	Perianal Disease Predicts Changes in Crohn's Disease Phenotype-Results of a Population-Based Study of Inflammatory Bowel Disease Phenotype. American Journal of Gastroenterology, 2008, 103, 3082-3093.	0.4	205
122	Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease. Personalized Medicine, 2008, 5, 233-248.	1.5	7
123	Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics and Genomics, 2008, 18, 434-438.	1.5	40
124	Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. European Journal of Gastroenterology and Hepatology, 2008, 20, 1238-1242.	1.6	41
125	Single Nucleotide Polymorphisms in IL4, OCTN1 and OCTN2 Genes in Association with Inflammatory Bowel Disease Phenotypes in a Caucasian Population in Canterbury, New Zealand. The Open Gastroenterology Journal, 2008, 2, 50-56.	0.1	5
126	Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World Journal of Gastroenterology, 2008, 14, 4652.	3.3	50

#	Article	IF	Citations
127	IL23R R381Q and ATG16L1 T300A Are Strongly Associated With Crohn's Disease in a Study of New Zealand Caucasians With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2007, 102, 2754-2761.	0.4	109
128	Has Toll-Like Receptor 4 Been Prematurely Dismissed as an Inflammatory Bowel Disease Gene? Association Study Combined With Meta-Analysis Shows Strong Evidence for Association. American Journal of Gastroenterology, 2007, 102, 2504-2512.	0.4	116
129	Comment: Breast-feeding During Maternal Use of Azathioprine. Annals of Pharmacotherapy, 2007, 41, 719-720.	1.9	12
130	Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. Journal of Medical Genetics, 2007, 45, 36-42.	3.2	47
131	IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics Journal, 2007, 7, 312-317.	2.0	47
132	Red Blood Cell Methotrexate Polyglutamate Concentrations in Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2007, 29, 619-625.	2.0	48
133	Thiopurine Treatment in??Inflammatory Bowel??Disease. Clinical Pharmacokinetics, 2007, 46, 803-804.	3.5	3
134	Association of DLG5 variants with inflammatory bowel disease in the New Zealand caucasian population and meta-analysis of the DLG5 R30Q variant. Inflammatory Bowel Diseases, 2007, 13, 1069-1076.	1.9	25
135	Effect of inflammatory bowel disease classification changes on NOD2 genotypeâ€“phenotype associations in a population-based cohort. Inflammatory Bowel Diseases, 2007, 13, 1220-1227.	1.9	40
136	Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease. Pharmacoeconomics, 2006, 24, 767-781.	3.3	83
137	The use ofÂlow dose methotrexate inÂrheumatoid arthritisâ€”are we entering aÂnew era ofÂtherapeutic drug monitoring andÂpharmacogenomics?. Biomedicine and Pharmacotherapy, 2006, 60, 678-687.	5.6	46
138	Two cases of thiopurine methyltransferase (TPMT) deficiency ? a lucky save and a near miss with azathioprine. British Journal of Clinical Pharmacology, 2006, 62, 473-476.	2.4	34
139	Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. British Journal of Clinical Pharmacology, 2006, 62, 453-456.	2.4	106
140	High incidence of CrohnÊ¼s disease in Canterbury, New Zealand: Results of an epidemiologic study. Inflammatory Bowel Diseases, 2006, 12, 936-943.	1.9	219
141	CARD15 allele frequency differences in New Zealand Maori: ancestry specific susceptibility to Crohn's disease in New Zealand?. Gut, 2006, 55, 580-580.	12.1	15
142	Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Internal Medicine Journal, 2005, 35, 580-585.	0.8	61
143	Azathioprine and 6â€mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1149-1157.	2.8	201
144	Gastrointestinal: Mycobacterium avium paratuberculosis and Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1943-1943.	2.8	9

#	Article	IF	Citations
145	Submental Surface Electromyographic Measurement and Pharyngeal Pressures During Normal and Effortful Swallowing. Archives of Physical Medicine and Rehabilitation, 2005, 86, 2144-2149.	0.9	111
146	Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. New Zealand Medical Journal, 2005, 118, U1324.	0.5	17
147	Reasons for Failure to Diagnose Colorectal Carcinoma at Colonoscopy. Endoscopy, 2004, 36, 499-503.	1.8	141
148	Penile and clitoral stimulation for faecal incontinence: external application of a bipolar electrode for patients with faecal incontinence. Colorectal Disease, 2004, 6, 54-57.	1.4	17
149	Surveillance for Dysplasia in Patients With Inflammatory Bowel Disease: A National Survey of Colonoscopic Practice in New Zealand. Diseases of the Colon and Rectum, 2004, 47, 314-322.	1.3	42
150	Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiology and Drug Safety, 2004, 13, 563-567.	1.9	142
151	Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. Molecular Diagnosis and Therapy, 2004, 8, 101-105.	1.1	11
152	A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clinica Chimica Acta, 2004, 341, 49-53.	1.1	26
153	Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics and Genomics, 2004, 14, 779-781.	5.7	107
154	Rapid Detection of Common CARD15 Variants in Patients with Inflammatory Bowel Disease. Molecular Diagnosis and Therapy, 2004, 8, 101-105.	1.1	3
155	Thiopurine S -methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 395-400.	3.7	84
156	Lack of Clinically Significant Interference by Spironolactone With the AxSym Digoxin II Assay. Therapeutic Drug Monitoring, 2003, 25, 112-113.	2.0	12
157	Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics and Genomics, 2003, 13, 627-632.	5.7	53
158	Macro-alkaline phosphatase due to IgG Î¹ complex: demonstration with polyethylene glycol precipitation and immunofixation. Annals of Clinical Biochemistry, 2002, 39, 523-525.	1.6	7
159	Aminoglycoside Dosage Regimens After Therapeutic Drug Monitoring. Clinical Pharmacokinetics, 2002, 41, 791-792.	3.5	6
160	Aminoglycoside Adaptive Resistance. Drugs, 2001, 61, 713-721.	10.9	79
161	Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?. British Journal of Clinical Pharmacology, 2001, 51, 627-630.	2.4	49
162	Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology and Therapeutics, 2001, 70, 217-227.	4.7	78

#	Article	IF	Citations
163	The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 2001, 52, 35-43.	2.4	11
164	The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 2001, 52, 35-43.	2.4	111
165	Small intestinal motor patterns in critically ill patients after major abdominal surgery. American Journal of Gastroenterology, 2001, 96, 2418-2426.	0.4	31
166	Small intestinal motor patterns in critically ill patients after major abdominal surgery. American Journal of Gastroenterology, 2001, 96, 2418-2426.	0.4	8
167	Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 2000, 14, 963-978.	3.7	268
168	Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Toxicological Reviews, 2000, 19, 293-312.	0.4	14
169	Simultaneous quantification of amoxycillin and metronidazole in plasma using high-performance liquid chromatography with photodiode array detection. Biomedical Applications, 1999, 731, 261-266.	1.7	54
170	Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. Alimentary Pharmacology and Therapeutics, 1999, 13, 1215-1219.	3.7	6
171	The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 1999, 47, 23-30.	2.4	132
172	Once Daily Aminoglycoside Therapy. Clinical Pharmacokinetics, 1999, 36, 89-98.	3.5	107
173	Lower oesophageal sphincter tone increases after induction of anaesthesia in pigs with full stomach. Canadian Journal of Anaesthesia, 1998, 45, 479-482.	1.6	8
174	Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy, 1996, 37, 1155-1164.	3.0	83
175	The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. Journal of Antimicrobial Chemotherapy, 1996, 38, 853-858.	3.0	25
176	Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Clinical Nephrology, 1996, 46, 183-6.	0.7	12
177	Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro. Antimicrobial Agents and Chemotherapy, 1995, 39, 132-136.	3.2	23
178	A suggested approach to onceâ€daily aminoglycoside dosing.. British Journal of Clinical Pharmacology, 1995, 39, 605-609.	2.4	296
179	Experience of onceâ€daily aminoglycoside dosing using a target area under the concentrationâ€time curve. Australian and New Zealand Journal of Medicine, 1995, 25, 230-235.	0.5	45
180	Aminoglycosides--50 years on. British Journal of Clinical Pharmacology, 1995, 39, 597-603.	2.4	170

#	Article	IF	Citations
181	A suggested approach to once-daily aminoglycoside dosing. British Journal of Clinical Pharmacology, 1995, 39, 605-9.	2.4	63
182	Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrobial Agents and Chemotherapy, 1994, 38, 2480-2482.	3.2	57
183	Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. Clinical Endocrinology, 1994, 40, 759-764.	2.4	103
184	Aminoglycoside dosing: time to change. Australian and New Zealand Journal of Medicine, 1994, 24, 359-361.	0.5	9
185	What is the Evidence for Once-Daily Aminoglycoside Therapy?. Clinical Pharmacokinetics, 1994, 27, 32-48.	3.5	84
186	Aminoglycoside toxicity and relation to dose regimen. Toxicological Reviews, 1994, 13, 207-34.	0.4	22
187	Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrobial Agents and Chemotherapy, 1992, 36, 1951-1957.	3.2	107